Applied Molecular Transport’s Proprietary Approach to Designing Oral Biologic Therapeutics Published in Tissue Barriers Journal SOUTH SAN FRANCISCO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (AMT), a clinical-stage biopharmaceutical company, today announced the first publication describing...

Applied Molecular Transport Presents Preclinical Data on AMT-101, an Oral GI-selective rhIL-10 at European Crohn’s and Colitis Organisation (ECCO) AMT-101, an oral GI-selective rhIL-10, showed potent activity at the site of disease in the colon in UC model with negligible systemic exposureOnce daily, oral AMT-101 efficiently crossed the...

Applied Molecular Transport Appoints Veteran Biopharmaceutical Executive, Liz Bhatt, to Role as Chief Business and Strategy Officer SOUTH SAN FRANCISCO, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Applied Molecular Transport (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Liz Bhatt to the...

Applied Molecular Transport Debuts with First Patient Dosed in Phase 1b Clinical Trial of AMT-101 in Adults with Ulcerative Colitis SOUTH SAN FRANCISCO, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Applied Molecular Transport (AMT), a clinical- stage biopharmaceutical company, today announced that the first patient has been dosed...